Anavex Life Sciences Corp (AVXL)

[Gator328]

Tried telling you all that there wouldn’t be data today. The audience at JPM conference are people like me, those who can read a balance sheet but don’t know what the endoplasmic reticulum does. It’s not a science conference, so any new data would go over most of the attendees heads.

He’s going to use the existing data to hammer home the point that Anavex is getting closer and closer to becoming cash flow positive, which is the language these investor clients of JP Morgan speak. There is value in that, too, even if many here are disappointed that there’s no new data.

I hope that nobody bought in expecting GREAT NEWS today. Writing was on wall and by now everyone should realize that there are some pumpers who try to generate excitement to sell their shares, just as there are bashers who create fear to short the stock.

2H 2023 is when we see the next big announcement — pediatric Rett data, and that will be how Blarcamesine gets to market. Anavex is for now a Rett stock with a promising Alzheimer’s pipeline. There’s nothing wrong with that.